Latest Content From Laura Elizabeth Lansdowne
The world is facing a health crisis of an unprecedented scale. The COVID-19 outbreak, caused by the SARS-CoV-2 virus, has rapidly spread across the globe and caused thousands of deaths. In this list, we highlight the efforts of five healthcare companies working to tackle the outbreak of COVID-19.VIEW
Researchers from Queen’s University Belfast will screen approximately 1,000 drugs, which have already received regulatory approval for other indications, to ascertain if they can reduce virus infection or replication and virus-induced inflammatory responses in airway epithelial cell models and to determine if they can therefore be repurposed to treat COVID-19 patients.VIEW
Technology Networks spoke with Dr Paul Hodgson, Associate Director of Business Development at VIDO-InterVac to learn more about their experience working with coronaviruses, the organization's manufacturing facilities, and the other antivirals and therapeutics they are currently testing in relation to COVID-19.
The Feinstein Institutes is collaborating with Gilead Sciences and Regeneron Pharmaceuticals in an effort to identify effective therapeutic treatments against COVID-19. Technology Networks recently had the pleasure of speaking with Kevin Tracey, CEO and President of the Feinstein Institutes for Medical Research to find out more.VIEW
Vivli, the Center for Clinical Research Data, recently issued a press release announcing the launch of the COVID-19 portal, designed to enable the sharing of completed interventional treatment trial data. Technology Networks spoke with Julie Wood, Vivli’s Director of Strategy and Operations, to learn more about the COVID-19 portal and discover how researchers can access the data within the portal.
CEL-SCI Corporation recently announced that it is utilizing LEAPS peptide technology in efforts to develop an immunotherapy against the novel coronavirus caused by SARS-CoV-2. Technology Networks, spoke with Daniel Zimmerman, Ph.D. Senior VP of Research, Cellular Immunology at CEL-SCI Corporation, to learn more about the LEAPS technology.VIEW
Cancer immunotherapies and viral vaccines that are nucleic acid-based can be challenging to formulate and require highly specific delivery systems. Commonly adopted delivery systems, such as lipid nanoparticles and viral vectors, can have limitations, therefore alternative approaches are being developed. Technology Networks recently spoke with Nigel Theobald, CEO and Founder of N4 Pharma, to learn more about nanoparticle drug delivery, the Nuvec® platform and its progress towards clinical trials.VIEW
We recently had the pleasure of speaking with William Levine, D.D.S., CannRx Founder and Chief Scientific Officer. Levine discusses CannRx’s mission to develop transformative, scientifically based, proprietary cannabis technologies, highlights some of the medical applications of cannabis-derived products, and explains why it is so important to analyze the various active compounds in cannabis.VIEW
Over-the-counter anti-inflammatory drugs, such as ibuprofen, should be avoided if you have coronavirus symptoms because they could worsen the condition, warns French authorities.VIEW